Skip to main content

Synaptic Dysfunction in Alzheimer Disease

Objectif

Given an overwhelming increase of dementia costs and an aging population, there is an urgent need for finding novel therapies for Alzheimer Disease (AD). We are, however, facing a large number of failed clinical trials and a retraction of the nervous system R&D programmes from several big pharmaceutical companies. Increased collaboration between academia and the private sector is required to overcome this challenge.
The “Synaptic Dysfunction in Alzheimer Disease” (SyDAD) project will significantly contribute to this approach by training a new generation of researchers with experience and full understanding of the requirements of academia, pharmaceutical companies, the clinics and the society.
The research programme will focus on synaptic dysfunction, the main connection point between pathology and cognitive decline in AD. Given the complementary expertise, SyDAD will have excellent opportunities to delineate the cross-talk between different pathways underlying synaptic dysfunction in AD and to identify novel pharmaceutical targets. For future implementation of the research findings into clinical trials, a drug discovery platform will be elaborated, utilising the industrial and clinical expertise in the network.
The early-stage researchers (ESRs) will be trained in this environment and provided with a mind-set of future commercial and clinical utilisation of their research findings. Apart from the innovative and collaborative approach of the research programme, the ESRs will also be provided with a training programme where cutting-edge methodology, innovation and transferable skills are key components.
The trained ESRs will have excellent intersectoral and interdisciplinary career opportunities and will, together with the SyDAD partners, provide a solid ground to tackle one of the major societal challenges of our century: Finding therapies to decrease the suffering and economic burden of AD patients.

Appel à propositions

H2020-MSCA-ITN-2015
Voir d’autres projets de cet appel

Coordinateur

KAROLINSKA INSTITUTET
Adresse
Nobels Vag 5
17177 Stockholm
Suède
Type d’activité
Higher or Secondary Education Establishments
Contribution de l’UE
€ 1 054 637,28

Participants (5)

UNIVERSITE DE BORDEAUX
France
Contribution de l’UE
€ 788 626,80
Adresse
Place Pey Berland 35
33000 Bordeaux
Type d’activité
Higher or Secondary Education Establishments
UNIVERSITA DEGLI STUDI DI MILANO
Italie
Contribution de l’UE
€ 774 183,96
Adresse
Via Festa Del Perdono 7
20122 Milano
Type d’activité
Higher or Secondary Education Establishments
DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV
Allemagne
Contribution de l’UE
€ 747 649,44
Adresse
Venusberg-campus 1/99
53127 Bonn
Type d’activité
Research Organisations
JANSSEN PHARMACEUTICA NV
Belgique
Contribution de l’UE
€ 250 560
Adresse
Turnhoutseweg 30
2340 Beerse
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
AXON NEUROSCIENCE SE
Slovaquie
Contribution de l’UE
€ 231 078,96
Adresse
Dvorakovo Nabrezie 10
81102 Bratislava
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)

Partenaires (5)

GOETEBORGS UNIVERSITET
Suède
Adresse
Vasaparken
405 30 Goeteborg
Type d’activité
Higher or Secondary Education Establishments
ASTRAZENECA AB
Suède
Adresse
Vastra Maelarhamnen
151 85 Sodertaelje
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
AlzeCure Discovery AB
Suède
Adresse
Ki Science Park, Hälsovägen 7
SE14157 Huddinge
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
SERENDIPITY INNOVATIONS AB
Suède
Adresse
Stureplan 15
111 45 Stockholm
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ALZHEIMER EUROPE
Luxembourg
Adresse
Rue Dicks 14
1417 Luxembourg
Type d’activité
Other